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ABSTRACT
Transglutaminase 2 (TG2), a multifunctional protein, is reported in regulating the 
cancer stem cell (CSC) phenotype in various cancers. Our previous work suggested 
the link between TG2 and Epithelial-Mesenchymal Transition (EMT) in colorectal 
cancer (CRC). Here we demonstrate the importance of TG2 in CSC development in 
human CRC cell lines HCT116 and SW620. CRC spheroid cells showed increased CSC 
characteristics over their monolayer cells with increased expression of CD44 and 
over expression of Oct3/4, Sox2 and Nanog. They also showed increased EMT and 
invasiveness, and enhanced expression of TG2. TG2 inhibition by its selective inhibitor 
1-155 reduced both spheroid formation and invasive potential of the spheroid cells. 
β-catenin, a mediator of stem cell maintenance, was overexpressed in the spheroid 
cells and could be attenuated by TG2 inhibition. Spheroid cells possessed increased 
angiogenesis stimulating ability via overexpression of Vascular Endothelial Growth 
Factor (VEGF). Increased VEGF was present in the culture media from spheroid cells 
when compared to monolayer cultures which could be reduced by selective inhibition 
by 1-155. Stemness and malignancy in the colorectal spheroid cells was associated 
with increased TG2, EMT, β-catenin and VEGF. Here we demonstrate that inhibiting 
TG2 reduces both stemness and angiogenic stimulating activity in CRC.
INTRODUCTION
There is a growing body of evidence showing that 
the formation and seeding of circulating tumour cells 
are highly dependent on a subpopulation of tumour cells 
with self-renewal potential and ability to differentiate 
into diverse tumour populations, this subpopulation 
of cells is called the cancer stem cells (CSCs) that can 
repopulate a tumour or seed a metastasis [1]. In colorectal 
cancer (CRC), patient survival depends on the stage of 
the disease, with metastasis accounting for poor patient 
prognosis. More recently, cancer researchers have 
become aware of the existence of colorectal CSCs, which 
possess self-renewing capabilities and essentially have 
the potential to acquire the many mutations that result 
in a cancerous cell [2]. These CSCs form the hierarchy 
of tumours and possess metastatic and drug-resistant 
phenotypes [3]. Wei et al (2012) have also shown that 
CSCs can sustain carcinogenesis, angiogenesis, metastasis 
and recurrence of CRC after remission [4].
In cancer, many of the embryonic and wound 
healing processes are subverted for pathological gains, 
one of which is Epithelial-Mesenchymal Transition 
(EMT), a process which enables epithelial cells to gain 
a mesenchymal-like phenotype [5]. Various studies are 
now providing evidence that EMT process is important in 
the development and acquisition of a CSC phenotype in 
various epithelial cancers [6, 7].
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Transglutaminase 2 (TG2), a multifunctional 
enzyme associated with pro-inflammatory responses and 
wound healing [8], has been reported to regulate EMT 
in various cancerous and fibrotic conditions [9, 10]. In 
recent times, TG2 expression has been reported to be 
increased in CSC-like enriched populations in ovarian 
cancer [11], breast cancer [12], squamous carcinomas 
[13] and mesotheliomas [14]. In addition β-catenin, 
an oncogenic protein that is widely upregulated in 
ovarian [15], gastric and CRC [16], has been shown to 
be important in the formation of CSC by targeting and 
activating the transcription of a number of genes which 
play an important role in maintenance of intestinal CSC 
[17]. Previous studies in CRC have shown that TG2 may 
potentiate nuclear accumulation of β-catenin in cancer 
cells [15, 18].
In this study, we show that by enrichment of a CSC 
population in vitro, TG2 is upregulated and that TG2 in 
association with β-catenin plays a role in the regulation 
of EMT and in the induction of the colorectal CSC 
phenotype, including tumour angiogenesis.
RESULTS
CD44 and transcription markers of stem cells 
are upregulated in spheroid cells
An in vitro spheroid formation assay has been 
widely documented as a means to selectively grow colon 
cancer cells with stem-like characteristics able to initiate 
tumour growth in immunodeficient mice and was used to 
enrich CRC cells with stem cell-like properties [19]. In 
Figure 1A, the morphology of monolayer and spheroids 
is shown. The tumour spheroid is composed of cellular 
aggregates which have contracted to form a compact 
spheroid structure. In whole cell lysates, the CD44 cell 
surface protein marker for CSCs shows a significant 
increase in expression in the SW620 and HCT116 
spheroid cells (SW620-S and HCT116-S, respectively) 
compared to their parental monolayer cells SW620-M and 
HCT116-M (Figure 1B). This finding was confirmed by 
flow cytometry that measured the cell surface expression 
of CD44 (Figure 1C). Western blotting was also used to 
detect the expression levels of transcription factors that 
upregulate cell stemness in both SW620 and HCT116 
cells. Figure 1B shows that the expression of transcription 
factors Sox2, Nanog and Oct3/4 were significantly 
increased in the spheroid cells compared to the monolayer 
cells (Figure 1B).
TG2 and EMT are upregulated in CRC
Following the characterisation and validation of 
the spheroid cells as possessing stem cell markers, the 
spheroid cells were characterised for TG2 expression 
in the whole cell lysates using Western blotting. Figure 
2A indicates a significant increase in TG2 expression 
in spheroid cells, SW620-S and HCT116-S compared 
to SW620 and HCT116 monolayer cells. A significant 
increase in the expression of a mesenchymal marker 
vimentin, while a significant decrease in an epithelial 
cell tight junction protein ZO-1, was detected in the 
spheroids of both HCT116 and SW620, compared to 
their respective monolayer counterparts. Additionally, 
to confirm the increase of EMT in the spheroids, the 
expression of transcription factors that regulate EMT 
were also determined by Western blotting which showed 
that both Slug and Twist were significantly increased 
(Figure 2A). We previously showed the importance of 
TG2 in EMT in SW620 cells using TG2 knockdown or 
pharmacological inhibition [18]. Figure 2B shows that 
knockdown of TG2 expression via a shRNA specific for 
human TG2 in HCT116 led to a significant reduction in 
the expression of EMT marker vimentin, and a reduction 
in the expression of EMT transcription factor Slug. 
In addition, ZO-1, an epithelial tight junction marker, 
was seen to be significantly increased following TG2 
knockdown by shRNA. Figure 2B shows that our TG2-
selective and cell permeable inhibitor 1-155 (1 µM for 48 
h) was able to reverse the EMT in HCT116 cells. In line 
with TG2 inhibition leading to a reversal of EMT in both 
SW620 and HCT116 cells, inhibition of TG2 by 1-155 or 
pre knockdown of TG2 by shRNA in monolayer cells can 
also lead to a reduction in spheroid formation in HCT116 
cells (Figure 2C) as previously demonstrated for SW620 
cells [18]. The structure of the selective TG2 inhibitor 
1-155 is shown in Figure 2D.
The effect of the empty vector (EV) and the 
vector containing TG2 shRNA was investigated in 
Supplementary Figure 1A, with expression of TG2 and 
EMT marker vimentin unaffected by the empty vector 
transduction when compared to wild type (wt) cells. 
Supplementary Figure 1B shows that TG2 inhibition by 
1-155 does not affect the cell viability of HCT116 cells as 
measured by Sodium 3’-[1-(phenylamino-carbonyl)-3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic 
acid hydrate (XTT) over a 48 h treatment period.
Colorectal stem-like cells display an invasive 
phenotype in vitro
An increased mesenchymal phenotype is found 
in the spheroids enabling these cells to mediate tissue 
invasion and metastasis [20]. We next attempted to 
compare the invasive properties of spheroid cells with 
stem cell-like properties against the parental monolayer 
cells, by utilising an ECM Transwell chamber invasion 
assay. As shown in Figure 3A and 3B, both SW620 and 
HCT116 spheroid cells demonstrated a significantly 
increased invasion in the collagen IV-coated Transwell 
chambers compared to their monolayer counterparts. 
Incubation of the spheroid cells with the TG2 selective 
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Figure 1: Spheroid cells display stem-like properties. (A) Representative phase-contrast microscope images (20× objective) of 
HCT116 monolayer (M), HCT116 spheres (S), SW620 monolayer and SW620 spheres. (B) Representative Western blot showing cell surface 
protein CD44, and transcription markers associated with stem cells Sox2, Nanog, and Oct3/4. The graph shows mean densitometry values 
± S.D. compared to controls (taken as 1.0) * indicates significantly different (p<0.05). n=3. (C) Flow cytometry analysis of CD44+ sub-
populations of SW620 and HCT116 monolayer and spheroids. Cells were stained with anti-human CD44- phycoerythrin-(PE) conjugated 
mouse antibody. Isotype-matched human antibodies served as controls. Isotype represented in blue and CD44 positive cells represented by 
the red graph. n=3.
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Figure 2: TG2 and EMT is upregulated in spheroid cells with stem cell-like properties. (A) Representative Western blot of 
whole cell lysates of parental adherent monolayer cells and spheroid cells from SW620 and HCT116 cells showing expression of TG2 and 
vimentin, transcription markers of EMT, Slug and Twist, and epithelial tight junction protein ZO-1. The graph shows mean densitometry 
values ± S.D. compared to controls (taken as 1.0). *, indicates significantly different (p<0.05). n=3. (B) The effect of TG2 knockdown or 
inhibition on EMT markers in HCT116 cells. Western blots of TG2, mesenchymal marker vimentin, and the transcription factor of EMT, 
Slug and expression of tight junction protein ZO-1 in whole cell lysates of TG2 knockdown cells and cells treated with TG2 selective 
cell-permeable inhibitor 1-155 (1μM). EV are cells containing empty vector. Ctrl represents vehicle control. The graph shows mean 
densitometry values ± S.D. compared to controls (taken as 1.0). * indicates significantly different (p<0.05). (C) HCT116 cells transduced 
with TG2 shRNA or incubated with TG2 inhibitor 1-155 reduces the enrichment of spheroids over 10 days as shown in the images captured 
using phase contrast microscopy. Cell viability shown in the graph was undertaken as described in the Materials and Methods. * indicates 
significantly different (p<0.05). (D) shows the structure of TG2 inhibitor 1-155..
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Figure 3: TG2 inhibition reduces invasiveness of CRC spheroid cells with stem cell properties. (A) Cell invasion of SW620 
spheroid cells and monolayer cells (B) Cell invasion of HCT116 spheroid cells and monolayer cells. Representative images of crystal violet 
stained cells that have invaded collagen IV in the transwell inserts. Images were captured using phase contrast microscopy (10X objective). 
The graphs show the cell count from each group. For 1-155 (1μM) treated cells, cells were pre-treated with 1-155 for 16h prior to seeding 
cells and were further treated with 1-155 (1μM) after cell seeding for the duration of the experiment. n=3. * Indicates significantly different 
(p<0.05). N.S-not significant (P>0.05)
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inhibitor 1-155 (1 μM) significantly reduced the invasive 
potential of the spheroid cells isolated from both SW620 
and HCT116.
Stem cell regulator β-catenin is upregulated in 
CRC stem cells
β-catenin is a regulator of stem cell maintenance 
and differentiation and is upregulated in CSCs [21]. In 
Figure 4A, spheroid cells exhibit over a 2-fold increase 
in β-catenin expression compared to monolayer cells 
and a significantly increased expression of its target 
gene cyclin D1 in spheroid cells suggesting that there 
is increased β-catenin nuclear transcription activity in 
these cells. TG2 has been reported to regulate β-catenin 
function in ovarian cancer cells [15] and SW620 CRCs 
[18]. TGFβ1 at 2.5 ng/ml was found to induce TG2 and 
β-catenin in HCT116 cells, while ERK1/2 inhibition by 
PD98059 (10 µM) significantly reduced the expression 
of TG2 and reduced the β-catenin expression levels back 
to pre-TGFβ1 stimulation (Figure 4B). Furthermore, TG2 
inhibition also led to a small but significant reduction 
in ERK1/2 activation and β-catenin expression. The 
effect of TGFβ1 on spheroid formation in HCT116 
cells indicated no significant effect on cell viability 
(Figure 4D). However, ERK1/2 inhibition by P98059 
significantly reduced the spheroid forming potential of 
HCT116 cells as determined by XTT, after 10 days of 
spheroid formation (Figure 4D). In contrast, we have 
previously shown that neither TGFβ1 treatment nor its 
inactivating antibody had any significant impact on the 
EMT status of SW620 cells, and that the basal protein 
expression of ERK1/2 in SW620 cells is already very 
low [18].
Expression of VEGF is increased in spheroid 
cells giving an enhanced angiogenic effect on 
endothelial cells
Tumours originating from CSCs are more vascular 
compared to tumours from monolayer cells [4]. In Figure 
5A, Human Umbilical Vein Endothelial Cells (HUVEC) 
cells seeded on Matrigel were treated with rhVEGF or 
conditioned media from the cultured SW620 spheroid cells 
over a 24-hour period. HUVECs treated with conditioned 
media for 6 h started to form cords and by 24 h endothelial 
cords were observed in both rhVEGF and condition media 
treated HUVEC cells. In the unconditioned spheroid cell 
media control and the minus VEGF control, endothelial 
cord formation was not evident at this time period. The 
spheroids were next characterised for their expression of 
VEGF which indicated increased cellular expression of 
VEGF, and also HIF1ɑ when compared to their respective 
monolayer cells (Figure 5B). Dot blot analysis showed 
VEGF was detectable in both the conditioned media from 
the cancer enriched CSCs isolated from the spheroids and 
the corresponding monolayer cultures, but in keeping 
with the increase in VEGF expression, in the spheroids, 
increased levels of VEGF were found in the conditioned 
media from the spheroid derived cells (Figure 5C). To 
confirm a potential relationship between TG2 and the 
presence of VEGF in the cell culture media, SW620 and 
HCT116 cells isolated from the spheroids were treated 
with 1-155. Reduced levels of VEGF were detected in the 
presence of 1-155, compared to the controls. (Figure 5D).
DISCUSSION
The use of in vitro spheroids in culture has been 
widely shown and used as a means to isolate, enrich, 
maintain or expand potential CSC subpopulations from 
various types of cancers [7, 22–24], and these CSC 
populations show stem cell-like properties and expression 
of CSC markers. Here, we characterised the spheroids 
obtained from highly invasive CRC cells SW620 and 
HCT116 for the expression of the stem cell marker 
CD44. We show that CD44 was upregulated in the 
spheroids cultured from both cells as assessed via flow 
cytometry and Western blotting. In addition, we also 
show that transcription factors of stemness, including 
Oct3/4, Nanog, and Sox2 [25], were highly expressed in 
the SW620 and HCT116 spheroid cells, compared to the 
parental monolayer cells.
Various studies are now providing evidence of a role 
for EMT in the acquisition of the CSC phenotype in CRC 
cells [20, 26, 27]. It has been proposed that while EMT is 
necessary for cells to dissociate, evade and disseminate 
(metastatise), the last metastatic step involves the growth 
of micrometastases into macroscopic metastases, and 
requires cells with self-renewal capacity and proliferative 
potential [28].
In our current study, we show that the EMT 
phenotype is heightened in spheroids of SW620 and 
HCT116 cells with a stem cell-like phenotype. While there 
is still a host of hypotheses concerning the origins of CSCs, 
numerous studies have suggested that EMT may facilitate 
CSC formation. Fan et al (2012) showed that transcription 
factors of EMT (Snail and Twist) confer a CSC phenotype 
by inducing the expression of pluripotency maintaining 
transcription factors associated with stem cells, such as 
Oct3/4, Sox2, Nanog in CRC cell lines HT29 and HCT116 
[27]. Here, we confirmed the increased expression of 
EMT transcription factors Slug and Twist in both SW620 
and HCT116 spheroid cells, compared to monolayer 
cells, which coincides with the expression of Oct3/4, 
Nanog and Sox2. Importantly, we demonstrated that 
the expression of TG2 was upregulated in the spheroids 
from both SW620 and HCT116 in comparison to the 
cells cultured in monolayers. Similar findings have been 
reported in ovarian, breast and squamous carcinomas [29]. 
Our previous study showed that selective TG2 inhibition 
reduced the spheroid forming capacity of SW620 
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Figure 4: Importance of β-catenin in CSC spheroid formation. (A) Representative Western blot of monolayer and spheroid 
cells from SW620 and HCT116 detecting the presence β-catenin and cyclin D1 expression in whole cell lysate. The graph shows mean 
densitometry values ± S.D. compared to controls (taken as 1.0) following normalising densitometry values ± against GAPDH. n=3. 
* indicates significantly different (p<0.05) (B) ERK activation increases β-catenin expression in HCT116 cells. Western blot of TG2, 
β-catenin and ERK activation in whole cell lysates of HCT116 cells treated with human recombinant TGFβ1 (2.5 ng/ml) and ERK inhibitor 
PD98059 (10 μM) for 48h. The graph shows mean densitometry values ± S.D. compared to controls (taken as 1.0) following normalising 
densitometry values ± S.D. against GAPDH. n=3. * indicates significantly different (p<0.05). (C) TG2 inhibition reduces ERK activation 
and β-catenin expression in HCT116 cells. Representative Western blot of TG2, β-catenin and ERK1/2 activation (p-ERK) in whole cell 
lysates of HCT116 monolayer cells following treatment with TG2 inhibitor 1-155 (1 µM) for 48 h. The graph shows mean densitometry 
values ± S.D. compared to controls (taken as 1.0) following normalising densitometry values against GAPDH. n=3. * indicates significantly 
different (p<0.05). (D) ERK1/2 inhibition reduces spheroid forming potential of HCT116 cells. HCT116 cells were seeded in spheroid 
forming media containing PD98059 (10 μM) or TGFβ1 (2.5 ng/ml) for 10 days and cell viability was performed using XTT. Control cells 
were treated with vehicle alone. n=3. *, significantly different from PD98059 treated cells. N.S, not significant.
Oncotarget4563www.oncotarget.com
Figure 5: Spheroids containing CRC stem-like cells induce angiogenesis in vitro. (A) HUVEC cells (3000 cells/well) were 
seeded into 96-well plates containing Matrigel and induced to form cord like structures. HUVEC cells were treated with 10 ng/ml rhVEGF 
which served as positive control, while DMEM/F12 basal medium was used as the negative control. Spheroid cell media without cell 
growth served as a control for the spheroid cell conditioned media (SCM) after spheroid cell growth for 18 h. Representative images are 
shown from cells treated for 24 h and phase contrast images using a 10× objective were taken at 2, 6 and 24 h periods. n=2. (B) Western 
Blot of monolayer and spheroid cells from SW620 and HCT116 detecting the presence VEGF and HIF1ɑ expression in whole cell lysate. 
The bar chart shows mean densitometry values ± S.D. compared to controls (taken as 1.0) following normalising of protein loading using 
GAPDH. n=3. * indicates significantly different (p<0.05). (C) Dot blot of monolayer (ML) and spheroid cells (CSC) from SW620 and 
HCT116 detecting the presence of VEGF in cell culture medium as described in the Materials and Methods. The graph shows mean 
densitometry values ± S.D. for VEGF normalised against media from monolayer cells (taken as 1.0). n=3. * indicates significantly different 
(p<0.05). (D) Representative Dot blot of VEGF present in conditioned media of spheroid cells (CSM) from SW620 and HCT116 cultured in 
the presence or absence of 1-155 as described in the Materials and Methods. The graph shows mean densitometry values ± S.D. for VEGF 
normalised against the vehicle control (taken as 1.0). n=3. * indicates significantly different (p<0.05).
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colorectal cells [18], with similar observations made in 
ovarian [11], breast [30] and squamous carcinomas [11, 
12, 22]. In this paper, we show that both TG2 shRNA and 
TG2 inhibition by its selective small molecule inhibitor 
1-155 developed in our group [31] can reduce spheroid 
formation in HCT116 cells. This suggests a role for TG2 
in CSC formation in vitro. We have also reported that TG2 
may induce EMT in CRCs and regulate the expression 
of both Slug and Twist. The mechanism by which TG2 
mediates EMT could be cell type specific and also 
dependent on its degree of progression. In our previous 
report, we showed that in non-metastatic primary CRC 
cells (RKO and SW480), TGFβ1 expression, release and 
signalling either through the canonical Smad signalling or 
via regulating Mitogen-activated protein kinases (MAPK) 
signalling was regulating EMT[18]. In contrast in the 
lymph metastatic cell line SW620, TG2 regulated EMT 
by facilitating nuclear translocation of β-catenin and 
demonstrated that the highly TG2-specific small molecule 
inhibitor 1-155 or silencing of TG2 by shRNA attenuated 
the EMT phenotype [18]. In this present study, we confirm 
that TG2 inhibition by 1-155 or TG2 knockdown by 
shRNA in HCT116 monolayer cells reduces EMT. As TG2 
is increased in CSCs it is very plausible that increased 
TG2 and EMT facilitates the stem cell formation in these 
CRCs in an in vitro tumour spheroid formation assay.
β-catenin is an oncoprotein whose deregulation is 
associated with CRCs [32] and plays an important role in 
the maintenance of intestinal stem cells. Nuclear β-catenin 
signalling in embryonic stem cells, depending on its 
binding partner can maintain pluripotency or play a role in 
the lineage decision/commitment process [21]. β-catenin 
has been shown to up-regulate pluripotency factors, e.g. 
Oct3/4, Nanog, and Sox2 [17] that are upregulated in the 
spheroids of both SW620 and HCT116 cells. Therefore, 
it is not surprising that β-catenin is also upregulated in 
these spheroid cells. We previously showed that TG2 
influenced β-catenin accumulation in the nuclei of SW620 
cells, and this may involve an extracellular or intracellular 
role, as TG2 was also found to complex with LRP5 a co-
receptor of Frizzle in the potentiation of Wnt signalling. 
The observation of transglutaminase involvement in Wnt 
signalling in ovarian cancer cells has also been reported 
by Condello et al [33]. In addition, intracellular TG2 was 
shown to complex with β-catenin, limiting β-catenin’s 
interaction with ubiquitin [18]. In the HCT116 and 
SW620 spheroid cells, both TG2 and β-catenin were 
upregulated, compared to monolayer cells, suggesting 
a role for TG2 in maintaining the CRC phenotype by 
facilitating β-catenin translocation into the nucleus. 
However, the upstream pathways regulating involvement 
of TG2 seem to differ in HCT116 and in SW620. In the 
HCT116 cells our data suggests a potential role for TG2 
in regulating the stabilisation of β-catenin by involvement 
of the MAPK pathway. Indeed, it has been suggested 
that ERK1/2 may activate the Wnt/β-catenin signalling 
[34]. In addition, Horst et al (2012) showed that ERK1/2 
activation resulted in nuclear accumulation of β-catenin 
in clinical human CRC cells, and concluded that MAPK 
signalling contributes significantly in determining the 
impact of Wnt activity on the stem cell phenotype in CRC 
cells [35]. In this current study, we demonstrate ERK1/2 
inhibition by its inhibitor PD98059 perturbed spheroid 
formation in vitro and TG2 inhibition by its inhibitor 
1-155 led to a reduction in ERK1/2 phosphorylation 
which correlated with decreased β-catenin expression. 
Taken together this suggests that involvement of TG2 
in β-catenin nuclear accumulation may be necessary 
for maintaining EMT and cancer stemness. To further 
confirm the nuclear activity of β-catenin, the expression 
of cyclin D1, a protein that is transcribed following 
β-catenin nuclear activity [36, 37], was evaluated. In this 
study, we show that cyclin D1 expression is higher in 
spheroid cells compared to monolayer cells, suggesting 
an increased nuclear transcriptional activity for β-catenin.
At this stage it is difficult to draw a definitive 
conclusion regarding the exact biochemical mechanism 
that regulates the expression of VEGF in the monolayer 
cells of both SW620 and HCT116 and which significantly 
increases in CSC rich spheroids. It has been reported that 
both EMT and VEGF production is linked to tumour 
progression and CSC formation and correlations have 
been made between EMT markers and VEGF expression 
in a number of different tumours [38, 39]. Wei et al (2012) 
reported that CSCs maintain angiogenesis and there are 
considerable reports also confirming β-catenin regulation 
of angiogenesis [4]. According to Zhang et al (2001), 
there are seven β-catenin/Tcf binding sites on the VEGF 
A (VEGFA) gene promoter [40]. In mice heterozygous 
for the multiple intestinal neoplasia gene (Min), there was 
increased redistribution of VEGF in proximity to those 
cells expressing nuclear β-catenin with a corresponding 
increase in vessel density [41]. It was further reported 
that in HeLa cells transfected with constructively active 
β-catenin, there was an up-regulated VEGF promoter 
activity by about 4.5-fold [40]. In Figure 5C, spheroid 
cells rich in CSCs overexpressing β-catenin demonstrate 
increased expression of VEGF and show increased levels 
of VEGF found in the cell culture medium compared 
to monolayer cells in both SW620 and HCT116 cells. 
Furthermore, HIF1ɑ, a transcription factor also involved 
in angiogenesis was also elevated in spheroid cells derived 
from SW620 and HCT116. Interestingly, treatment of cells 
with the selective TG2 inhibitor 1-155 reduced the amount 
of VEGF found in the cell growth medium from the 
spheroid cells. Taken together, an important role for TG2 
in the crosstalk between colorectal CSCs and endothelial 
cells can be proposed in which TG2 is important for 
both EMT and nuclear β-catenin accumulation which 
leads to increased VEGF expression. In both EMT and 
β-catenin accumulation, TG2 appears to be an important 
player which may explain why TG2 inhibition results in 
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a reduction of VEGF in the culture medium. It is also 
possible that extracellular TG2 released by CSCs may 
increase the bio-availability of VEGF by facilitating its 
matrix binding as suggested by Wang et al in endothelial 
cell tubule formation [42]. The neovascularisation of CSCs 
in tumours then potentiates tumour growth and metastasis 
by favouring extravasation.
In summary, our data show that TG2 expression is 
upregulated in colorectal CSCs and that TG2 plays a role 
in maintaining the CSC phenotype by inducing EMT and/
or by fostering the nuclear activity of β-catenin. We also 
show that TG2 is important in the accumulation of VEGF 
in the extracellular environment of CRC cells encouraging 
endothelial cell tubule formation leading to tumour 
vascularisation and subsequent tumour progression. 
Since binding of the cell permeable irreversible inhibitor 
1-155 to TG2 fixes the enzyme in its open confirmation 
blocking both transamidation and GTP/GDP binding [31], 
at this stage we cannot rule out either of these functions 
in the development of the CSC phenotype. However, 
our result indicate that the binding of TG2 to a selective 
small molecule irreversible inhibitor reduces EMT and 
attenuates the invasive and angiogenesis stimulating 
activity of CSCs, strongly suggesting TG2 is an ideal 
therapeutic target for inhibiting the CSC phenotype in 
highly aggressive CRCs.
MATERIALS AND METHODS
Reagents and antibodies
Peptidomimetic cell-permeable TG2 selective 
inhibitor 1-155 was synthesized at Aston University 
[31]. ERK1/2 inhibitor PD98059 and recombinant 
human TGFβ1 (rhTGFβ1) were purchased from CST 
(London, UK) and R&D Systems (Bio-Techne Ltd, 
Abingdon, UK), respectively. Antibodies for Western blot 
detection of Twist, Slug, β-catenin, Nanog, Oct3/4, Sox2, 
CD44, VEGF, GADPH, vimentin, total ERK1/2, and 
phosphorylated ERK1/2 (T202/Y204) were purchased 
from Santa Cruz Biotechnology Inc. Anti-ZO-1 antibody 
was purchased from life Technologies, anti-TG2 antibody 
was from Thermo Fisher (Loughborough, UK).
Cell culture conditions
Human CRC cell lines SW620 and HCT116, a kind 
gift from Dr Chris Tselepsis (University of Birmingham, 
UK) were cultured in a humidified atmosphere at 37ºC and 
5% (v/v) CO2. All the cells were cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) (Lonza, Slough, UK) 
containing 10% FBS (Thermo Fisher, Loughborough, 
UK), 1% (v/v) nonessential amino acids and penicillin/
streptomycin (100U/ml and 100μg/ml respectively) used 
for experiments, unless otherwise indicated. Enrichment 
of spheroid cells with stem-like characteristics was 
performed by culturing cells on polyhema coated low 
attachment plates; cells were cultured in serum-free 
DMEM/F12 (1:1) (Lonza, Slough, UK) containing 
2% (v/v) serum free supplement B27 (Thermo Fisher, 
Loughborough, UK), 20 ng/ml EGF, 0.4% bovine serum 
albumin and 4 μg/ml insulin. Spheroid cells were also 
cultured in humidified atmosphere at 37°C and 5% (v/v) 
CO2.
To collect the cells from the tumour spheroids the 
spheroids cultured in suspension for 7-10 days were 
collected by centrifugation at 300 ×g for 5 min, washed 
with sterile Phosphate buffered Saline (PBS), pH 7.4, and 
then the cells within the spheroid dispersed into single 
cells by treatment with pre-warmed 0.25% (w/v) trypsin 
in 2mM EDTA for 5 min at 37°C.
Lentiviral transduction
In order to silence TG2 in CRCs, lentiviral constructs 
containing wild-type shRNA that targets human TG2 
was used to transduce the CRCs as previously described 
[43]. The CRCs were seeded into 6-well plates or 35 mm 
Petri dishes and allowed to reach 80% confluence. The 
complete growth media was then changed and renewed 
with 700 µl of fresh medium with 100 µl of lentiviral 
particles containing TG2 shRNA targeting human TG2 
in each well and incubated for 24 h under standard cell 
culture conditions. A second infection was carried out the 
next day by adding 700 µl medium and 100 µl lentivirus 
per well and cells were incubated for another 24 h.shRNA 
sequences #1 5’-CCACCCACCATATTGTTTGAT- 3’#2 
5’-ACAGCAACCTTCTCATCGAGT-3’
Cell treatment
CRCs were treated with the TG2 selective 
irreversible peptidomimetic cell-permeable inhibitor 1-155 
[31] at 1 µM. CRCs were also treated with rhTGFβ1 (2.5 
ng/ml) (R&D Systems, Oxford, UK) or mouse anti-human 
TGFβ neutralising antibody (R&D Systems, Oxford, UK). 
Control cells were treated with treatment vehicle DMSO 
(0.01%) or PBS.
Western blotting
Cells were lysed in cell lysis buffer as described 
previously [42]. Equal amounts of protein were separated 
by SDS-PAGE and electroblotted onto nitrocellulose 
membranes as previously described [43, 44]. After 
incubation with primary and HRP-conjugated secondary 
antibodies, antigen-antibody complexes were visualized 
using enhanced chemiluminescence (Amersham 
Biosciences, Piscataway, USA). Densitometry was 
performed with ImageJ 1.49 for windows. Images were 
captured by a chemiluminescent image analyser Syngene 
G-box F3 (Cambridge, UK). The membranes were 
reprobed for GAPDH, an equal loading control used to 
Oncotarget4566www.oncotarget.com
normalize the signal obtained for target proteins. The 
ratios against the control treatment were analysed as 
described previously [31]. The intensity of the bands were 
normalised against GAPDH band.
Dot blotting
Equal numbers of viable cells from either the 
monolayer culture or the dispersed spheroids were seeded 
into 24-well plates (2.5×105/well) in complete growth 
media for 4 h. After which the complete growth media 
was replaced with ITS (Sigma-Aldrich, Haverhill, UK) 
supplemented serum-free cell culture media. Cells were 
incubated for 18 h and the cell culture media collected and 
assayed by dot blotting to detect the presence of VEGF 
which was performed as described previously [44].
Matrigel cord formation assay
Endothelial cord formation was measured by a 
Matrigel endothelial cord formation assay as described 
by Wang et al (2013) [42]. 96 well plates were coated 
with Matrigel (Corning, Loughborough, UK). Human 
Umbilical Vein Endothelial Cells HUVECs (Promocell, 
Heidelberg, Germany) were seeded 1.5×105 cells/well onto 
matrigel-coated wells and treated with conditioned media 
from spheroid cells or non-conditioned control media with 
or without rhVEGF as positive and negative controls.
Cell invasion assay
Invasion assays were performed on serum-starved 
cells cultured in serum-free ITS (Insulin transferrin 
sodium selenite media supplement- Sigma Aldrich, 
UK) containing media for 16 h prior to seeding 1.0×105 
cells/100μl in same media onto the collagen IV-coated 
chamber Transwell inserts of a 24-well plate. 600 μl of 
10% serum containing complete media were added to the 
accompanying 24-well plate of the chamber, and cells 
incubated for 24 h under cell culture conditions to allow 
for invasion. Following incubation, the Transwell inserts 
were removed from the plates and the media was discarded 
and non-migrated cells were removed. The cells that were 
embedded in the Transwell insert were fixed in 70% (v/v) 
ethanol for 10 min. After this the inserts and the Transwell 
membrane were allowed to dry. 0.2% crystal violet was 
used to stain the cells at room temperature [45]. Following 
staining, the inserts were removed, washed gently 3 times 
with PBS to remove the excess crystal violet, and the 
Transwell membranes were allowed to dry. The invasive 
cells were viewed underneath an inverted microscope and 
cell count was made under 10× objective. Images of the 
cells were also captured.
Cell viability assay
XTT was used to measure cell viability of monolayer 
cells or cells collected from dispersed spheroids as 
described previously [23].
Immunophenotyping by flow cytometry
Adherent monolayer cells and cells derived from 
tumour spheres were collected by trypsinisation and 
suspended in PBS containing 3% bovine serum albumin 
(BSA) (Sigma-Aldrich, UK). The cells were then initially 
blocked with 10% (v/v) normal human immunoglobulin 
(Ig) (Grifols, Cambridge, UK) for 30 min at 4 °C, after 
which cells were incubated with phycoerythrin-(PE) 
conjugated mouse anti-CD44 (Immunotools, Friesoythe, 
Germany) (1:100 dilution) in 3% (w/v) BSA in PBS, 
pH 7.4, for 2 h at 4ºC. Non-specific fluorescence was 
determined by incubating cells with isotype-matched 
control phycoerythrin-conjugated antibodies IgG2a 
(Immunotools, Friesoythe, Germany). Cells were then 
washed 4 times by centrifugation at 400 ×g in 3% (w/v) 
BSA in PBS, pH 7.4. Immunoreactivity for each CD44 
was assessed by flow cytometry using a Beckman Coulter 
FC500 flow cytometer and data were analysed using 
Flowing Software 2.5.1 analysis Software.
Statistical analyses
Data were expressed as mean ± S.D. The data shown 
are derived from a representative experiment undertaken 
in triplicate (unless otherwise stated). Comparisons 
among different groups were performed by either t-test 
or analysis of variance using one-way ANOVA using the 
GraphPad Instat software package. Significant differences 
between control and treatment groups were analysed 
by Bonferroni’s Multiple Comparison Test. Statistical 
significant difference between data sets as defined in the 
text by p<0.05 (two-sided).
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